CN117417421A - 一种突变体膜蛋白复合物纳米孔及其应用 - Google Patents
一种突变体膜蛋白复合物纳米孔及其应用 Download PDFInfo
- Publication number
- CN117417421A CN117417421A CN202310040838.2A CN202310040838A CN117417421A CN 117417421 A CN117417421 A CN 117417421A CN 202310040838 A CN202310040838 A CN 202310040838A CN 117417421 A CN117417421 A CN 117417421A
- Authority
- CN
- China
- Prior art keywords
- cpsc
- cpsd
- porin
- mutant
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title abstract description 9
- 102000018697 Membrane Proteins Human genes 0.000 title abstract description 6
- 108010052285 Membrane Proteins Proteins 0.000 title abstract description 6
- 102220482197 Calcium/calmodulin-dependent protein kinase type 1_K49A_mutation Human genes 0.000 claims abstract description 53
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 50
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 43
- 108010013381 Porins Proteins 0.000 claims abstract description 29
- 238000000746 purification Methods 0.000 claims abstract description 9
- 238000010276 construction Methods 0.000 claims abstract description 6
- 239000013604 expression vector Substances 0.000 claims abstract description 6
- 102000007739 porin activity proteins Human genes 0.000 claims abstract 13
- 150000007523 nucleic acids Chemical group 0.000 claims description 21
- 239000012528 membrane Substances 0.000 claims description 20
- 239000010410 layer Substances 0.000 claims description 19
- 238000001514 detection method Methods 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 238000012163 sequencing technique Methods 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 150000003904 phospholipids Chemical group 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 108010038807 Oligopeptides Proteins 0.000 claims description 4
- 102000015636 Oligopeptides Human genes 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 239000002356 single layer Substances 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 238000010353 genetic engineering Methods 0.000 abstract description 4
- 238000012916 structural analysis Methods 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 35
- 102000017033 Porins Human genes 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 239000002808 molecular sieve Substances 0.000 description 7
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 7
- 239000002131 composite material Substances 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 230000008602 contraction Effects 0.000 description 5
- 238000007672 fourth generation sequencing Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 238000013480 data collection Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000012520 frozen sample Substances 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- UKDDQGWMHWQMBI-UHFFFAOYSA-O 1,2-diphytanoyl-sn-glycero-3-phosphocholine Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)CC(=O)OCC(COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CC(C)CCCC(C)CCCC(C)CCCC(C)C UKDDQGWMHWQMBI-UHFFFAOYSA-O 0.000 description 1
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- -1 DPhPC phospholipid Chemical class 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 101150091586 cpsC gene Proteins 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007671 third-generation sequencing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明属于基因工程和遗传工程领域,公开了一种突变体膜蛋白复合物纳米孔及其应用,包括孔蛋白复合物突变体CpsC‑CpsDK49A的表达载体构建,蛋白的表达纯化、结构解析。
Description
技术领域
本发明涉及一种表征目标多核苷酸的方法,特别涉及一种经过改造的突变体CpsC-CpsDK49A蛋白复合物及其应用,属于基因工程和遗传工程领域。
背景技术
作为近年来发展迅猛的第三代测序技术,纳米孔测序依据孔道类型可分为固态孔和生物纳米孔,生物纳米孔即能够允许底物通过的孔道蛋白,以下统称为生物纳米孔。生物纳米孔测序技术的基本原理是在电场力的作用下,带电核酸底物能够通过孔道蛋白,当核酸通过生物纳米孔时,不同碱基及其修饰能够影响通过生物纳米孔的电流强度,产生不同的电流信号,通过对电流信号的解析,可以获得通过纳米孔的核酸的碱基信息。作为影响纳米孔测序技术的关键因素,孔道蛋白的性质至关重要,而孔道蛋白种类单一是目前纳米孔测序技术所面临的主要问题之一,以常用的孔道蛋白——大肠杆菌CsgG突变体为例,由于其孔道收缩区厚度能够容纳4-5个碱基,使得单次记录的电流信号是由4-5个碱基的阻碍作用产生,造成后续信号分析难度较大,导致准确率难以达到二代测序的水平。因此,需要发掘具有新型收缩区的孔道蛋白,一方面能够增加纳米孔的可选择种类,另一方面减少电流信号解析难度,进一步提高测序的准确率。
发明内容
本发明针对现有来源于大肠杆菌的纳米孔蛋白收缩区较厚,导致电流信号检测涉及连续多个核苷酸协同作用的缺点,寻找到一种收缩区厚度较薄的突变体CpsDK49A和CpsC组成的蛋白复合物纳米孔,该蛋白复合物收缩区仅厚度仅 从而减少连续多核苷酸的数量,降低电流信号解码难度,提高碱基分辨效率。同时,目前能够用于测序的孔蛋白种类比较少,所以,本发明提供了一种新型纳米孔蛋白,该突变体蛋白复合物形成稳定的十六聚体,能够作为生物纳米孔,并具备进一步优化改造的潜力。
第一方面,本发明提供一种孔蛋白复合物突变体CpsC-CpsDK49A,其中所述孔蛋白复合物突变体的氨基酸包括SEQ ID NO:1和SEQ ID NO:2所示的序列或与SEQ ID NO:1和SEQ ID NO:2具有至少99%、98%、97%、96%、95%、90%、80%、70%、60%或50%同一性的序列。
第二方面,本发明提供编码上述孔蛋白复合物突变体CpsC-CpsDK49A的核酸序列。
在一些实施方案中,所述核酸序列选自:
1)如SEQ ID NO:3示;
2)与SEQ ID NO:3所示的核酸序列至少具有85%的同源性,且编码SEQ IDNO:1和2所示氨基酸序列的核酸序列;
3)与1)或2)互补的核酸序列。
在一些实施方案中,同源性在85%-99%之间。
在一些实施方案中,同源性为85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%。
第三方面,本发明提供包含上述编码基因的重组载体,优选的载体序列为SEQ IDNO:4所示的CpsC-CpsDK49A_pET28a。
第四方面,本发明提供一种基因工程化的细胞或微生物,所述的细胞或微生物含有上述重组载体,或者其基因组中整合上述编码基因;优选地,所述微生物为大肠杆菌。
第五方面,本发明提供包含上述孔蛋白复合物突变体CpsC-CpsDK49A的产品。
在一些实施方案中,所述产品是组合物或试剂盒。
第六方面,本发明提供上述孔蛋白复合物突变体CpsC-CpsDK49A的制备方法,包括以下步骤:
1)构建孔蛋白复合物突变体CpsC-CpsDK49A的表达载体;
2)孔蛋白复合物突变体CpsC-CpsDK49A表达、纯化。
第七方面,本发明提供一种膜层,所述膜层中嵌入上述孔蛋白复合物突变体CpsC-CpsDK49A。
在一些实施方案中,所述膜层是磷脂膜层。
在一些实施方案中,所述膜层是磷脂单层膜层。
第八方面,本发明提供一种检测系统,包括上述孔蛋白复合物突变体CpsC-CpsDK49A或者上述膜层。
第九方面,本发明提供一种装置,包括上述孔蛋白复合物突变体CpsC-CpsDK49A、上述膜层或者上述检测系统。
第十方面,本发明提供上述孔蛋白复合物突变体CpsC-CpsDK49A、上述膜层或上述检测系统在制备样品测序和/或检测的装置中的应用。
在一些实施方案中,所述样品为核苷酸、核酸、氨基酸、寡聚肽、多肽、蛋白质中的一种或多种。
第十一方面,本发明提供上述孔蛋白复合物突变体CpsC-CpsDK49A、上述膜层、上述检测系统或上述装置在样品测序和/或检测中的应用。
在一些实施方案中,所述样品为核苷酸、核酸、氨基酸、寡聚肽、多肽、蛋白质中的一种或多种。
有益效果
根据已有生物纳米孔测序结果,纳米孔蛋白收缩区(核酸底物电流检测区,也可称为电流信号的读取头)的厚度会决定连续核酸过孔的数量,从而影响电流信号复杂度。本发明人通过冷冻电镜技术,解析了高分辨率突变体CpsC-CpsDK49A复合物纳米孔结构结构分析发现CpsC-CpsDK49A纳米孔蛋白收缩区宽度为/>厚度/>(附图7)。
附图说明
图1是野生型CpsC-CpsD复合物蛋白表达纯化图;
图2是野生型CpsC-CpsD蛋白复合物分子筛结果图;
图3是突变体CpsC-CpsDK49A复合物蛋白表达纯化图;
图4是突变体CpsC-CpsDK49A蛋白复合物分子筛结果图;
图5是突变体CpsC-CpsDK49A蛋白复合物冷冻电镜map图;
图6是突变体CpsC-CpsDK49A蛋白复合物纳米孔整体结构图;
图7是突变体CpsC-CpsDK49A蛋白复合物纳米孔收缩区整体构象图;
图8是突变体CpsC-CpsDK49A蛋白复合物纳米孔的电流曲线。
具体实施方式
下文将结合具体实施例对本发明的技术方案做更进一步的详细说明。应当理解,下列实施例仅为示例性地说明和解释本发明,而不应被解释为对本发明保护范围的限制。凡基于本发明上述内容所实现的技术均涵盖在本发明旨在保护的范围内。
除非另有说明,以下实施例中使用的原料和试剂均为市售商品,或者可以通过已知方法制备。
实施例1:野生型及突变体CpsC-CpsDK49A蛋白复合物表达载体构建与蛋白的制备
1.突变体CpsC-CpsDK49A蛋白复合物表达载体构建
野生型及突变体CpsC-CpsDK49A来源于Streptococcus agalactiae
蛋白CpsC,NCBI Reference Sequence:WP_001033068.1(SEQID1)
蛋白CpsD NCBI Reference Sequence:WP_000197406.1(突变体序列为SEQID2)
该蛋白表达基因通过人工合成的方式获得,合成过程进行适用于大肠杆菌表达的密码子优化并引入CpsD上第49位氨基酸的突变(SEQID:3),该基因序列中,CpsC和CpsDK49A基因序列之间引入一段包含10个核苷酸的序列,合成后基因直接连接到pET-28a载体上,蛋白CpsC的N端添加6×his,作为亲和纯化标签,蛋白CpsDK49A的C端添加strep标签用于蛋白检测。载体构建由基因合成公司完成,获得表达载体序列见SEQID:4.
在合成的表达突变体蛋白复合物的质粒基础上,利用定点突变PCR方法,获得野生型CpsC-CpsD蛋白复合物蛋白表达质粒。
引物序列如下
F:AAATCCACTACTTCAACAAGTTTAGCTTTATC
R:TTGTTGAAGTAGTGGATTTTCCTTCCCCTTCCCTAACAG
PCR体系如下(30μL):
PCR程序如下:
PCR反应产物加入Dpn1,37℃消化1hr后转化DH5α细胞,挑点测序,选取正确克隆进行后续实验。
2.野生型和突变体CpsC-CpsDK49A复合物纳米孔蛋白表达、纯化
野生型和突变体CpsC-CpsDK49A复合物纳米孔蛋白经过Ni柱亲和层析、分子筛纯化后,蛋白纯度较高(附图1,野生型;附图3,突变体),蛋白性质均一(附图2,野生型;附图4,突变体),通过分子筛图判断可知和野生型CpsC-CpsD复合物相比,CpsC和CpsDK49A能够形成稳定复合物。
表达纯化步骤如下:
1)将野生型和突变体CpsC-CpsDK49A表达质粒(SEQID4)转入BL21(DE3),进行表达。37℃200rpm获取种子液1mL后转入1L LB培养基,37℃200rpm至OD600为1.2,降温至26℃0.2mM IPTG(异丙基硫代半乳糖苷)诱导过夜;
2)4000rpm收集菌体,使用裂解buffer重悬(20mL/L菌),高压破碎后18000rpm 4℃离心1小时,收集沉淀膜组分;
3)使用溶膜buffer(10mL/L菌)重悬膜组分,4℃磁力搅拌1小时进行膜蛋白抽提,18000rpm 4℃离心1小时,收集上清膜蛋白组分;
4)上清中加入终浓度30mM的咪唑后与溶膜buffer平衡后的Ni beads进行孵育,4℃结合1小时后进行亲和纯化;
5)将上清和Ni beads导入柱子中,重力自然流穿;10mL wash buffer清洗,5mLElution buffer洗脱蛋白;
6)目的蛋白进行分子筛纯化后SDS-PAGE检测纯度,结果如附图1所示,分子筛结果如附图2所示。
裂解buffer:20mM Tris-HCl,150mM NaCl,pH 8.0
溶膜buffer:20mM Tris-HCl,150mM NaCl,pH 8.0,1%DDM
Wash buffer:20mM Tris-HCl,150mM NaCl,pH 8.0,0.5%DDM,50mM咪唑
Elution buffer:20mM Tris-HCl,150mM NaCl,pH 8.0,0.1%DDM,200mM咪唑
分子筛buffer:20mM Tris-HCl,150mM NaCl,pH 8.0,0.02%GDN
实施例2:突变体CpsC-CpsDK49A复合物纳米孔蛋白原子水平结构
得到纯度和均一度较高的突变体CpsC-CpsDK49A复合物纳米孔蛋白后(实施例1),本发明人利用冷冻电镜技术,解析了其分辨率为的近原子水平结构。
冷冻电镜结构解析步骤如下:
1)准备筛选好的样品,并在相同的冻样条件下制备几个备用样品,选取6个合适的样品上到Talos Arctica 200kV高端电镜中;
2)上样后等待真空和温度稳定后,开启镜筒在低倍下选择合适的方形孔。这一步和冷冻样品的筛选类似,其目的使选择合适的方形孔用于后面数据的收集;
3)根据电镜的机时空余以及每个方形孔能够采集的照片数量,计算大概需要选择的方形孔数量,选择完成后进行地图的拍摄;
4)地图拍摄过程中,我们可以离线选择地图中能够用于数据收集的孔,这样可以节省一部分的时间;
5)待地图拍摄完成后既可以对电镜进行调机,以备数据的收集工作。主要包括电镜的合轴、背底扣除及数据收集基本参数(欠焦量-1.5μm到-2.5μm,电子计量拍照帧数32帧和pixl size/>)的设置;
本发明人后续经过数据处理,结构解析,得到了其电子密度,整体如附图5所示,整体map为8聚体结构,单体位置如图所示(附图5左图为顶视图,右图为侧视图),右图标注该纳米孔蛋白复合物跨膜区位置。随后,通过同源建模,结构搭建、精修获得了突变体CpsC-CpsDK49A纳米孔蛋白复合物氨基酸的原子坐标(附图6,左图为侧视图,右图为顶视图)。结构分析可见,CpsC-CpsDK49A纳米孔蛋白复合物收缩区有别于大肠杆菌纳米孔蛋白的三层结构,收缩区区宽度为(附图7左和右上),收缩区厚度薄(附图7右下)仅为/>
实施例3:突变体CpsC-CpsDK49A复合物纳米孔蛋白电流信号检测
在获得CpsC-CpsDK49A突变体纳米孔蛋白复合物后,本发明人对这些蛋白的电流性质进行检测。本发明采用人工形成磷脂单层膜(DPhPC),再嵌入单个纳米孔蛋白,后在180mV电压下记录电流变化。
嵌入纳米孔步骤如下:
在缓冲液(600mM KCl,75mM K3[Fe(CN)6,25mM K4[Fe(CN)6]·3H2O,100mMHepes,pH 8.0)中,由嵌入到DPhPC磷脂双分子层的纳米孔获得电信号测量值。在实现单孔插入磷脂双分子层后,用2mL缓冲液(600mM KCl,75mM K3[Fe(CN)6,25mM K4[Fe(CN)6]·3H2O,100mM Hepes,pH 8.0)流过系统以除去残留的过量纳米孔。分别记录CpsC-CpsDK49A突变体纳米孔蛋白复合物在磷脂膜上的电流信号,记录结果如图所示(附图8)。
由电流信号可见,该复合物纳米孔过孔电流为0.37nA,电流比较平稳,但自发阻碍作用相对比较强。电流信号的这些特征表明CpsC-CpsDK49A突变体纳米孔蛋白具有对线性生物大分子链如核酸链进行测序的能力,通过适当的优化可以获得可用于测序的纳米孔突变体。
序列信息
SEQ ID1
>CpsC
MHHHHHHNKIANTEVEINIFNLLKKLWKKKFLITFVAIAFATAGLFYSLFIVTPQYISSTRIYVINPNTPNNS
ITAQDLQAGSFLANDYKEIITSTDVLEKVISSEKLNYPSSQLLQKITVSILKDTRVISISVEDANPKMSQKLA
NSVREAAVSKIKAVTQVEDITTLEKGNLPKAPSSPNIKKNVLIGFIVGAGLSTIVLVIMGILDDRVNTEEDIE
KALGLTSLGIVPDLNKLSEQ ID2
>CpsDK49A
MTRLEIVDSKLRQAKKTEEYFNAIRTNIQFSGKENKILAITSVREGEGASTTSTSLALSLAQAGFKTLLIDA
DTRNSVMSGTFKATGTIKGLTNYLSGNADLGDIICETNVPRLMVVPSGKVPPNPTALLQNAYFNKMIEAI
KNIFDYIIIDTPPIGLVVDAAIIASACDGFVLVTQAGRIKRNYVEKAKEQMEQSGSKFLGIILNKVNESVAT
YGDYGNYGKRDRKRKWSHPQFEK
SEQ ID3>
CpsC-CpsDK49A
ATGCATCATCATCATCATCATAATAAAATAGCTAATACAGAAGTTGAAATAAATATATTCAACCTTT
TAAAAAAATTGTGGAAAAAGAAATTTTTAATCACATTTGTTGCCATTGCATTTGCAACAGCTGGACTTTTCTATAGTCTTTTTATTGTTACGCCACAATATATTTCTTCAACAAGGATATATGTCATTAACCCTAATACCCCTAATAATAGTATTACTGCACAAGATCTACAAGCGGGGAGTTTTCTTGCCAATGACTATAAGGAGATTATTACGTCTACTGACGTTCTAGAAAAAGTTATTTCTTCTGAAAAATTGAATTATCCTTCGTCTCAGTTGTTGCAAAAAATAACAGTTTCTATTTTAAAAGATACACGTGTTATTTCAATATCGGTCGAAGATGCTAATCCAAAAATGTCTCAAAAATTAGCAAATTCAGTTAGAGAAGCAGCAGTTTCAAAAATCAAGGCAGTTACTCAAGTAGAGGATATCACTACTCTTGAGAAGGGAAATTTACCTAAAGCACCATCTTCTCCTAATATTAAAAAGAATGTACTAATCGGGTTTATTGTTGGTGCAGGATTATCAACTATTGTTTTAGTTATTATGGGTATTTTGGATGATCGTGTTAATACTGAAGAAGATATTGAAAAGGCCCTAGGACTTACTTCTTTAGGTATAGTACCAGATTTGAATAAACTTTAAGGAGAATATAATGACTCGTTTAGAAATAGTTGATAGCAAGTTAAGACAAGCAAAAAAAACAGAAGAATACTTCAATGCGATCCGTACAAACATACAGTTTAGTGGAAAGGAAAATAAAATTCTTGCAATTACCTCTGTTAGGGAAGGGGAAGGAGCATCCACTACTTCAACAAGTTTAGCTTTATCTTTAGCTCAAGCAGGATTTAAAACATTATTAATTGATGCGGATACTAGGAACTCTGTTATGTCTGGAACCTTTAAAGCAACTGGAACTATTAAAGGCTTGACGAATTATTTATCAGGTAATGCAGATCTTGGAGATATTATCTGTGAAACCAATGTTCCTAGACTGATGGTCGTTCCTTCAGGGAAAGTACCACCAAATCCAACAGCATTACTTCAGAACGCTTATTTTAATAAGATGATTGAAGCTATTAAAAATATATTTGATTATATTATCATCGATACTCCACCTATTGGTTTAGTTGTTGATGCCGCAATAATCGCTAATGCTTGCGATGGTTTTATTTTAGTAACCCAAGCAGGTAGAATAAAACGTAATTATGTTGAAAAAGCAAAAGAACAGATGGAACAAAGTGGTTCAAAGTTCTTAGGTATTATTCTTAATAAAGTTAGTGAATCTGTTGCAACTTACGGCGATTATGGAAATTACGGAAAAAGGGATAGAAAAAGGAAGTGGTCTCACCCTCAGTTCGAAAAATAA
SEQ ID4
>CpsC-CpsDK49A_pET28a
TGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAATTAATTCTTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGTTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTAGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAA
GATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCAC
CGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTC
AGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACT
CTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAA
GTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAAC
GGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCG
TGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCA
GGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTG
TCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATG
GAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCT
TTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGC
CGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCTGATGCGGTA
TTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCAATGGTGCACTCTCAGTACAATCTGCTCTGA
TGCCGCATAGTTAAGCCAGTATACACTCCGCTATCGCTACGTGACTGGGTCATGGCTGCGCCCCGAC
ACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGC
TGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGGCAG
CTGCGGTAAAGCTCATCAGCGTGGTCGTGAAGCGATTCACAGATGTCTGCCTGTTCATCCGCGTCCA
GCTCGTTGAGTTTCTCCAGAAGCGTTAATGTCTGGCTTCTGATAAAGCGGGCCATGTTAAGGGCGGT
TTTTTCCTGTTTGGTCACTGATGCCTCCGTGTAAGGGGGATTTCTGTTCATGGGGGTAATGATACCGA
TGAAACGAGAGAGGATGCTCACGATACGGGTTACTGATGATGAACATGCCCGGTTACTGGAACGTT
GTGAGGGTAAACAACTGGCGGTATGGATGCGGCGGGACCAGAGAAAAATCACTCAGGGTCAATGCC
AGCGCTTCGTTAATACAGATGTAGGTGTTCCACAGGGTAGCCAGCAGCATCCTGCGATGCAGATCCG
GAACATAATGGTGCAGGGCGCTGACTTCCGCGTTTCCAGACTTTACGAAACACGGAAACCGAAGAC
CATTCATGTTGTTGCTCAGGTCGCAGACGTTTTGCAGCAGCAGTCGCTTCACGTTCGCTCGCGTATCG
GTGATTCATTCTGCTAACCAGTAAGGCAACCCCGCCAGCCTAGCCGGGTCCTCAACGACAGGAGCAC
GATCATGCGCACCCGTGGGGCCGCCATGCCGGCGATAATGGCCTGCTTCTCGCCGAAACGTTTGGTG
GCGGGACCAGTGACGAAGGCTTGAGCGAGGGCGTGCAAGATTCCGAATACCGCAAGCGACAGGCC
GATCATCGTCGCGCTCCAGCGAAAGCGGTCCTCGCCGAAAATGACCCAGAGCGCTGCCGGCACCTG
TCCTACGAGTTGCATGATAAAGAAGACAGTCATAAGTGCGGCGACGATAGTCATGCCCCGCGCCCA
CCGGAAGGAGCTGACTGGGTTGAAGGCTCTCAAGGGCATCGGTCGAGATCCCGGTGCCTAATGAGT
GAGCTAACTTACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAG
CTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCCAGGGTGGTTTTT
CTTTTCACCAGTGAGACGGGCAACAGCTGATTGCCCTTCACCGCCTGGCCCTGAGAGAGTTGCAGCA
AGCGGTCCACGCTGGTTTGCCCCAGCAGGCGAAAATCCTGTTTGATGGTGGTTAACGGCGGGATATA
ACATGAGCTGTCTTCGGTATCGTCGTATCCCACTACCGAGATATCCGCACCAACGCGCAGCCCGGAC
TCGGTAATGGCGCGCATTGCGCCCAGCGCCATCTGATCGTTGGCAACCAGCATCGCAGTGGGAACG
ATGCCCTCATTCAGCATTTGCATGGTTTGTTGAAAACCGGACATGGCACTCCAGTCGCCTTCCCGTTC
CGCTATCGGCTGAATTTGATTGCGAGTGAGATATTTATGCCAGCCAGCCAGACGCAGACGCGCCGAG
ACAGAACTTAATGGGCCCGCTAACAGCGCGATTTGCTGGTGACCCAATGCGACCAGATGCTCCACGC
CCAGTCGCGTACCGTCTTCATGGGAGAAAATAATACTGTTGATGGGTGTCTGGTCAGAGACATCAAG
AAATAACGCCGGAACATTAGTGCAGGCAGCTTCCACAGCAATGGCATCCTGGTCATCCAGCGGATA
GTTAATGATCAGCCCACTGACGCGTTGCGCGAGAAGATTGTGCACCGCCGCTTTACAGGCTTCGACG
CCGCTTCGTTCTACCATCGACACCACCACGCTGGCACCCAGTTGATCGGCGCGAGATTTAATCGCCG
CGACAATTTGCGACGGCGCGTGCAGGGCCAGACTGGAGGTGGCAACGCCAATCAGCAACGACTGTT
TGCCCGCCAGTTGTTGTGCCACGCGGTTGGGAATGTAATTCAGCTCCGCCATCGCCGCTTCCACTTTT
TCCCGCGTTTTCGCAGAAACGTGGCTGGCCTGGTTCACCACGCGGGAAACGGTCTGATAAGAGACAC
CGGCATACTCTGCGACATCGTATAACGTTACTGGTTTCACATTCACCACCCTGAATTGACTCTCTTCC
GGGCGCTATCATGCCATACCGCGAAAGGTTTTGCGCCATTCGATGGTGTCCGGGATCTCGACGCTCT
CCCTTATGCGACTCCTGCATTAGGAAGCAGCCCAGTAGTAGGTTGAGGCCGTTGAGCACCGCCGCCG
CAAGGAATGGTGCATGCAAGGAGATGGCGCCCAACAGTCCCCCGGCCACGGGGCCTGCCACCATAC
CCACGCCGAAACAAGCGCTCATGAGCCCGAAGTGGCGAGCCCGATCTTCCCCATCGGTGATGTCGG
CGATATAGGCGCCAGCAACCGCACCTGTGGCGCCGGTGATGCCGGCCACGATGCGTCCGGCGTAGA
GGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAA
TTCCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGCATCATCATCATCATCAT
AATAAAATAGCTAATACAGAAGTTGAAATAAATATATTCAACCTTTTAAAAAAATTGTGGAAAAAG
AAATTTTTAATCACATTTGTTGCCATTGCATTTGCAACAGCTGGACTTTTCTATAGTCTTTTTATTGTT
ACGCCACAATATATTTCTTCAACAAGGATATATGTCATTAACCCTAATACCCCTAATAATAGTATTAC
TGCACAAGATCTACAAGCGGGGAGTTTTCTTGCCAATGACTATAAGGAGATTATTACGTCTACTGAC
GTTCTAGAAAAAGTTATTTCTTCTGAAAAATTGAATTATCCTTCGTCTCAGTTGTTGCAAAAAATAAC
AGTTTCTATTTTAAAAGATACACGTGTTATTTCAATATCGGTCGAAGATGCTAATCCAAAAATGTCTC
AAAAATTAGCAAATTCAGTTAGAGAAGCAGCAGTTTCAAAAATCAAGGCAGTTACTCAAGTAGAGG
ATATCACTACTCTTGAGAAGGGAAATTTACCTAAAGCACCATCTTCTCCTAATATTAAAAAGAATGT
ACTAATCGGGTTTATTGTTGGTGCAGGATTATCAACTATTGTTTTAGTTATTATGGGTATTTTGGATG
ATCGTGTTAATACTGAAGAAGATATTGAAAAGGCCCTAGGACTTACTTCTTTAGGTATAGTACCAGA
TTTGAATAAACTTTAAGGAGAATATAATGACTCGTTTAGAAATAGTTGATAGCAAGTTAAGACAAGC
AAAAAAAACAGAAGAATACTTCAATGCGATCCGTACAAACATACAGTTTAGTGGAAAGGAAAATAA
AATTCTTGCAATTACCTCTGTTAGGGAAGGGGAAGGAGCATCCACTACTTCAACAAGTTTAGCTTTA
TCTTTAGCTCAAGCAGGATTTAAAACATTATTAATTGATGCGGATACTAGGAACTCTGTTATGTCTGG
AACCTTTAAAGCAACTGGAACTATTAAAGGCTTGACGAATTATTTATCAGGTAATGCAGATCTTGGA
GATATTATCTGTGAAACCAATGTTCCTAGACTGATGGTCGTTCCTTCAGGGAAAGTACCACCAAATC
CAACAGCATTACTTCAGAACGCTTATTTTAATAAGATGATTGAAGCTATTAAAAATATATTTGATTAT
ATTATCATCGATACTCCACCTATTGGTTTAGTTGTTGATGCCGCAATAATCGCTAATGCTTGCGATGG
TTTTATTTTAGTAACCCAAGCAGGTAGAATAAAACGTAATTATGTTGAAAAAGCAAAAGAACAGAT
GGAACAAAGTGGTTCAAAGTTCTTAGGTATTATTCTTAATAAAGTTAGTGAATCTGTTGCAACTTAC
GGCGATTATGGAAATTACGGAAAAAGGGATAGAAAAAGGAAGTGGTCTCACCCTCAGTTCGAAAAA
TAACTCGAGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAG
TTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGG
GTTTTTTGCTGAAAGGAGGAACTATATCCGGAT
以上,对本发明的实施方式进行了说明。但是,本发明不限定于上述实施方式。凡在本发明的精神和原则之内,所做的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (11)
1.一种孔蛋白复合物突变体CpsC-CpsDK49A,其中所述孔蛋白复合物突变体的氨基酸包括SEQ ID NO:1和SEQ ID NO:2所示的序列或与SEQ ID NO:1和SEQ ID NO:2序列具有至少99%、98%、97%、96%、95%、90%、80%、70%、60%或50%同一性的序列。
2.编码权利要求1所述孔蛋白复合物突变体CpsC-CpsDK49A的核酸序列;
1)如SEQ ID NO:3示;
2)与SEQ ID NO:3所示的核酸序列至少具有85%的同源性,且编码SEQ IDNO:1和2所示氨基酸序列的核酸序列;
3)与1)或2)互补的核酸序列;
优选地,同源性在85%-99%之间;
优选地,同源性为85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%。
3.包含权利要求2所述核酸序列的重组载体。
4.一种基因工程化的细胞或微生物,所述的细胞或微生物含有权利要求3所述的重组载体,或者其基因组中整合权利要求2所述的核酸序列;优选地,所述微生物为大肠杆菌。
5.包含权利要求1所述孔蛋白复合物突变体CpsC-CpsDK49A的组合物或试剂盒。
6.权利要求1所述孔蛋白复合物突变体CpsC-CpsDK49A的制备方法,包括以下步骤:
1)构建孔蛋白复合物突变体CpsC-CpsDK49A的表达载体;
2)孔蛋白复合物突变体CpsC-CpsDK49A表达、纯化。
7.一种膜层,所述膜层中嵌入权利要求1所述的孔蛋白复合物突变体CpsC-CpsDK49A;
优选地,所述膜层是磷脂膜层;
优选地,所述膜层是磷脂单层膜层。
8.一种检测系统,包括权利要求1所述的孔蛋白复合物突变体CpsC-CpsDK49A或者权利要求7所述的膜层。
9.一种装置,包括权利要求1所述的孔蛋白复合物突变体CpsC-CpsDK49A、权利要求7所述的膜层或者权利要求8所述检测系统。
10.权利要求1所述的孔蛋白复合物突变体CpsC-CpsDK49A、权利要求7所述的膜层或者权利要求8所述检测系统在制备样品测序和/或检测的装置中的应用;优选地,所述样品为核苷酸、核酸、氨基酸、寡聚肽、多肽、蛋白质中的一种或多种。
11.权利要求1所述的孔蛋白复合物突变体CpsC-CpsDK49A、权利要求7所述的膜层或者权利要求8所述检测系统或权利要求9所述装置在样品测序和/或检测中的应用;优选地,所述样品为核苷酸、核酸、氨基酸、寡聚肽、多肽、蛋白质中的一种或多种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310040838.2A CN117417421B (zh) | 2023-01-12 | 2023-01-12 | 一种突变体膜蛋白复合物纳米孔及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310040838.2A CN117417421B (zh) | 2023-01-12 | 2023-01-12 | 一种突变体膜蛋白复合物纳米孔及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117417421A true CN117417421A (zh) | 2024-01-19 |
CN117417421B CN117417421B (zh) | 2024-07-23 |
Family
ID=89527250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310040838.2A Active CN117417421B (zh) | 2023-01-12 | 2023-01-12 | 一种突变体膜蛋白复合物纳米孔及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117417421B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010034018A2 (en) * | 2008-09-22 | 2010-03-25 | University Of Washington | Msp nanopores and related methods |
CN105801676A (zh) * | 2016-04-13 | 2016-07-27 | 东南大学 | 一种突变MspA蛋白单体及其表达基因和应用 |
WO2020155242A1 (zh) * | 2019-01-30 | 2020-08-06 | 深圳市梅丽纳米孔科技有限公司 | 一种突变NfpAB纳米孔、测试系统及制作方法与应用 |
US20220412948A1 (en) * | 2019-11-19 | 2022-12-29 | Rijksuniversiteit Groningen | Artificial nanopores and uses and methods relating thereto |
-
2023
- 2023-01-12 CN CN202310040838.2A patent/CN117417421B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010034018A2 (en) * | 2008-09-22 | 2010-03-25 | University Of Washington | Msp nanopores and related methods |
CN105801676A (zh) * | 2016-04-13 | 2016-07-27 | 东南大学 | 一种突变MspA蛋白单体及其表达基因和应用 |
WO2020155242A1 (zh) * | 2019-01-30 | 2020-08-06 | 深圳市梅丽纳米孔科技有限公司 | 一种突变NfpAB纳米孔、测试系统及制作方法与应用 |
CN111499705A (zh) * | 2019-01-30 | 2020-08-07 | 深圳市梅丽纳米孔科技有限公司 | 一种突变NfpAB纳米孔、测试系统及制作方法与应用 |
US20220412948A1 (en) * | 2019-11-19 | 2022-12-29 | Rijksuniversiteit Groningen | Artificial nanopores and uses and methods relating thereto |
Non-Patent Citations (2)
Title |
---|
ANDREW H LASZLO等: "MspA nanopore as a single-molecule tool: From sequencing to SPRNT", METHODS, vol. 105, 1 August 2016 (2016-08-01), pages 75 - 89, XP029659424, DOI: 10.1016/j.ymeth.2016.03.026 * |
葛元洁等: "单分子实时测序及其在微生物表观遗传学中的应用", 微生物学通报, vol. 44, no. 1, 24 May 2016 (2016-05-24), pages 186 - 199 * |
Also Published As
Publication number | Publication date |
---|---|
CN117417421B (zh) | 2024-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230079731A1 (en) | Novel protein pores | |
CN113480620B (zh) | 孔蛋白单体的突变体、蛋白孔及其应用 | |
JP2024133465A (ja) | 細孔 | |
CN109627344B (zh) | cAMP荧光探针及其应用 | |
KR101261870B1 (ko) | 폴리믹신 b 또는 e 생합성 효소 및 이를 코딩하는 유전자 군 | |
CN107723368B (zh) | 一组用于肾细胞癌分子分型的基因及其应用 | |
US20220412948A1 (en) | Artificial nanopores and uses and methods relating thereto | |
CN113470751A (zh) | 一种蛋白纳米孔氨基酸序列的筛选方法、蛋白纳米孔及其应用 | |
CN117417421B (zh) | 一种突变体膜蛋白复合物纳米孔及其应用 | |
CN117417418B (zh) | 一种具有超高热稳定性的纳米孔突变体及其应用 | |
CN117886907B (zh) | 一种pht纳米孔突变体蛋白及其应用 | |
Schuster et al. | Protein expression strategies for identification of novel target proteins | |
Saidijam et al. | Active membrane transport and receptor proteins from bacteria | |
CN117384260B (zh) | 一种新型纳米孔蛋白突变体及其应用 | |
Saidijam et al. | The MFS efflux proteins of gram-positive and gram-negative bacteria | |
WO2024138565A1 (zh) | 纳米孔蛋白及其突变体和应用 | |
Nagem et al. | Getting the most out of X-ray home sources | |
WO2024138424A1 (zh) | 纳米孔蛋白及其应用 | |
WO2024138425A1 (zh) | 一种新型纳米孔蛋白及其应用 | |
CN110794129A (zh) | 细胞内检测生物分子间相互作用及其调控因子的方法与所用试剂 | |
WO2023123347A1 (zh) | 解旋酶bch1x及其用途 | |
CN115820618A (zh) | Sc1-70抗原截短体、其制备方法和应用 | |
CN115960924A (zh) | 重组jo-1抗原的制备方法和应用 | |
EP4196608A1 (en) | Nucleoside-5'-oligophosphates tagged with positively-charged polymers, nanopores incorporating negative charges, and methods and systems using the same | |
CN115820677A (zh) | 重组slo抗原的制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |